Clinical trials: Adjuvant Treatment
Melanoma
A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in participants with completely resected, cutaneous BRAF mutation-positive melanoma at high risk for…
- Trial name
- BRIM8 (NCT01667419)
- Testing
- Vemurafenib
- Where
- 207 sites in United States, Argentina and 27 more
- Volunteers
- 498 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
The purpose of this study is to evaluate the role of neoadjuvant immunotherapy and to demonstrate high pathologic complete response (pCR) and near pCR rates in melanoma participants with clinically detectable nodal disease and a…
- Trial name
- CheckMate 7UA (NCT04495010)
- Testing
- Nivolumab, Ipilimumab
- Where
- 118 sites in United States, Australia and 14 more
- Sponsor
- Bristol-Myers Squibb
Asthma
Adjuvant Therapy for Severe Asthma by an Oxyhydrogen Generator With Nebulizer
The purpose for the trial is intended to evaluate safety and effectiveness of an oxyhydrogen generator with nebulizer in an adjuvant therapy for patients with severe asthma.
- Trial name
- NCT02883582
- Testing
- oxyhydrogen, oxygen
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Asclepius Meditec Inc.
Bipolar Disorder
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.
Bipolar disorder is a psychiatric illness with clinical characteristics of mixed mania, grandiose delusions, and suicidality. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of patients with…
- Trial name
- NCT00154323
- Testing
- Oxcarbazepine
- Volunteers
- 55 people
- Sponsor
- Novartis
Glioblastoma
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: A Screening/Baseline Period of 21 days.
- Trial name
- BRIDGES (NCT07195591)
- Testing
- GammaTile®, External Beam Radiation Therapy, Temozolomide
- Where
- 13 sites in United States
- Volunteers
- 766 people
- Sponsor
- GT Medical Technologies, Inc.
Breast Cancer
Patient's Anastrozole Compliance to Therapy Programme
Approximately 60 specialised clinics and 420 office based gynaecologists or oncologists will participate in this in practice evaluation program (NIS).
- Trial name
- PACT (NCT00555867)
- Testing
- Anastrozole
- Volunteers
- 4,923 people
- Sponsor
- AstraZeneca
COVID-19 Respiratory Infection
HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients
The primary purpose of this study is to evaluate the efficacy of HC-1119 as an adjuvant treatment for hospitalized COVID-19 male and female patients.
- Trial name
- NCT04986176
- Testing
- HC-1119
- Volunteers
- 602 people
- Sponsor
- Applied Biology, Inc.
Colorectal Cancer
A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer
This study will evaluate the safety and tolerability of capecitabine (Xeloda) in participants who have undergone surgery for colon cancer.
- Trial name
- NCT02581423
- Testing
- Capecitabine
- Where
- 6 sites in Bulgaria
- Volunteers
- 63 people
- Sponsor
- Hoffmann-La Roche
Differentiated Thyroid Cancer
Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
The study is designed to evaluate the clinical efficacy, safety and tolerability of selumetinib with radioactive iodine therapy in patients with differentiated thyroid cancer.
- Trial name
- ASTRA (NCT01843062)
- Testing
- Selumetinib, Radioactive Iodine Therapy
- Where
- 45 sites in United States, Brazil and 6 more
- Volunteers
- 233 people
- Sponsor
- AstraZeneca
Nasopharyngeal Cancer
Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
The purpose of this study is to determine the safety and potential of dendritic cells therapy and secretomes therapy for advanced nasopharyngeal cancer.
- Trial name
- NCT05261750
- Testing
- Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy), Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy)
- Where
- Indonesia
- Volunteers
- 15 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Breast Cancer
Tumour Registry Breast Cancer
The registry aims to collect and analyse information on the antineoplastic treatment of breast cancer in daily routine practice of office-based and clinic-based medical oncologists in Germany.
- Trial name
- TMK (NCT01351584)
- Volunteers
- 4,500 people
- Sponsor
- iOMEDICO AG
Myelodysplastic Syndromes
Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, increase the number of white blood cells and platelets found in bone…
- Trial name
- NCT00513578
- Testing
- PR1 leukemia peptide vaccine, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Vaccine Company